Abstract
Drug discovery is a complex and costly endeavor, requiring multidisciplinary know-how, interdisciplinary collaboration, tenacity, and a bit of luck. For these reasons, the search for new chemical agents to treat human disease has traditionally been undertaken only within the walls of industry. While the pharmaceutical industry is often successful where it focuses its attention, it generally focuses only on those areas that are allowed by corporate financial realities. Sadly, this means that diseases effecting small populations of patients may go untreated. As a society we should not be content with this situation and must make a priority of the development of new models that will allow and encourage drug discovery in disease areas that are neglected by pharma. In this presentation, I will describe one such model that has been established to find treatments for neurodegenerative diseases.
Keywords: Harvard Center for Neurodegeneration and Repair, Drug Discovery, Medicinal Chemistry, Laboratory for Drug Discovery in Neurodegeneration, pharmaceutical company
Current Alzheimer Research
Title: A New Model for Academics Based Drug Discovery
Volume: 4 Issue: 5
Author(s): Ross L. Stein
Affiliation:
Keywords: Harvard Center for Neurodegeneration and Repair, Drug Discovery, Medicinal Chemistry, Laboratory for Drug Discovery in Neurodegeneration, pharmaceutical company
Abstract: Drug discovery is a complex and costly endeavor, requiring multidisciplinary know-how, interdisciplinary collaboration, tenacity, and a bit of luck. For these reasons, the search for new chemical agents to treat human disease has traditionally been undertaken only within the walls of industry. While the pharmaceutical industry is often successful where it focuses its attention, it generally focuses only on those areas that are allowed by corporate financial realities. Sadly, this means that diseases effecting small populations of patients may go untreated. As a society we should not be content with this situation and must make a priority of the development of new models that will allow and encourage drug discovery in disease areas that are neglected by pharma. In this presentation, I will describe one such model that has been established to find treatments for neurodegenerative diseases.
Export Options
About this article
Cite this article as:
Stein L. Ross, A New Model for Academics Based Drug Discovery, Current Alzheimer Research 2007; 4 (5) . https://dx.doi.org/10.2174/156720507783018280
DOI https://dx.doi.org/10.2174/156720507783018280 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Does Human Alpha-Synuclein Behave Like Prions?
CNS & Neurological Disorders - Drug Targets New Challenges in CNS Repair: The Immune and Nervous Connection
Current Immunology Reviews (Discontinued) Recent Advances in Neuroinflammation Therapeutics: PPARs/LXR as Neuroinflammatory Modulators
Current Pharmaceutical Design Neurogenic plasticity of mesenchymal stem cell, an alluring cellular replacement for traumatic brain injury
Current Stem Cell Research & Therapy Potential Drugs Targeting Microglia: Current Knowledge and Future Prospects
CNS & Neurological Disorders - Drug Targets Antioxidant Therapy for the Treatment of Oxidative Stress Associated to Cancer and Cancer- Related Anorexia/Cachexia
Current Nutrition & Food Science Nanoneuromedicines for Neurodegenerative Diseases
Nanoscience & Nanotechnology-Asia IAPs, their Antagonists and their Role in Neurological Disease and Cancer
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Emerging Use of Nanotechnology in the Treatment of Neurological Disorders
Current Pharmaceutical Design LPS-induced Murine Neuroinflammation Model: Main Features and Suitability for Pre-clinical Assessment of Nutraceuticals
Current Neuropharmacology Proteins in Microglial Activation - Inputs and Outputs by Subsets
Current Protein & Peptide Science The Neurotrophic and Antiangiogenic Functions of PEDF: A Reflection of its Variable Phosphorylation States
Current Genomics Apo-E4 Allele in Conjunction with Aβ42 and Tau in CSF: Biomarker for Alzheimers Disease
Current Alzheimer Research Therapeutic Options in Prevention and Treatment of Aspartoacylase Gene Mutation Resulting Abnormalities in Canavan Disease
Current Pharmacogenomics Phenylbutyric Acid: Simple Structure - Multiple Effects
Current Pharmaceutical Design Riluzole Exhibits No Therapeutic Efficacy on a Transgenic Rat model of Amyotrophic Lateral Sclerosis
Current Neurovascular Research Proteomics Annotation of Lipid Rafts Modified by Virus Infection
Combinatorial Chemistry & High Throughput Screening A Glimpse of Matrix Metalloproteinases in Diabetic Nephropathy
Current Medicinal Chemistry Exercise-Induced MicroRNA Regulation in the Mice Nervous System is Maintained After Activity Cessation
MicroRNA subject Index To Volume 1
Current Drug Targets - CNS & Neurological Disorders